Learn, Analyse & Invest
only with
only with
+91
Download Orca
Godavari Drugs Ltd.
Godavari Drugs
₹ 0.00
0.00 (0.00)%
NSE
BSE
Healthcare
Small-cap - With a market cap of ₹1.25 Cr.
| EX-Date | Purpose |
|---|---|
| 10 05 2021 | Inter alia, approved: 1,To take note of disclosure of interest by Directors alonB with their shareholdings under Section 184 of the Companies Act, 2013 2. To take note of Annual disclosures under the SEBt {SAST} Regulations 2011 from the promoter and Promoier Group of the Company under Regulatior 30(1) & 30 (2) 3. To take note of declarations made by the Directors under section 164(2) of the Companies Act, 2013 4. To take note of Disclosures made by the directors of the Company under the SEB| (prohibition of lnsider Trading) ReBulations 2015 5. To take note of declaration on lndependence from the tndependent Directors as per Section 149(7) of the Companies Act, 2013 6. To Consider and take note bfthe working and operations ofthe Vigil Mechanism 7. To take a note on the Complaance of Regulation 40(9)for the half year ended 31st March, 2021. 8. Totake note ofthe Statement of investor complaints duringthe quarterended 31st March,2021 9. To discuss and take note of the Compliance report placed before the Board, with regard to compliances under the various applicable Laws and Acts 10. To take on record Corporate Governance Report as per Reg. 27(2)(a) of SEBt (Listing Obligations And Disclosure Requirements) Regulations, 2015 for the Quarter ended on 31st March, 2021 11. To take on record Compliance Certificate as per Re8. 7(3) of SEB| (Listin8 Obligations And Disc osure Requirements) Regulations, 2015 for the Half year ended on 31st March, 2021 12. To take note of the Listing Fees paid towards the depositories 13. To Accept the resiSnation of cS Narendra Maddineni from the post of company Secretary and Compliance officer 14. To consider end approve lhe appointment of CS Rashmi Agarwal as Company Secretary and Compliance officer of the Company. 15. Anv other business with the permission of Chairman |
| 16 06 2021 | Audited Results |
| 14 08 2021 | Quarterly Results |
| 12 11 2021 | Quarterly Results |
| 14 02 2022 | Quarterly Results |
| 19 04 2022 | Audited Results Inter alia to: 1. To Consider and approve the Audited Standalone Financial Results of the Company for the Fourth Quarter and Financial Year ended 31st March, 2022; 2. To discuss and approve Draft Boards Report and Draft Management Discussion and Analysis Report for the Financial Year ended 31st March, 2022; 3. To discuss and approve Draft Notice of 34th Annual General Meeting of the company 4. To discuss, consider and approve other Agenda points as circulated to the Board Members 5. Anyother Business with the permission of the Chairman |
| 13 08 2022 | Quarterly Results |
| 12 11 2022 | Quarterly Results |
| 14 02 2023 | Quarterly Results |
| 29 05 2023 | Audited Results |
| 11 08 2023 | Quarterly Results |
| 14 11 2023 | Quarterly Results |
| 13 02 2024 | Quarterly Results (Revised) |
| 14 02 2024 | Quarterly Results |
| 14 11 2024 | Quarterly Results |
| 12 02 2025 | Quarterly Results |
| 29 05 2025 | Audited Results & Quarterly Results |
| 13 08 2025 | A.G.M. & Quarterly Results |
| 14 11 2025 | Quarterly Results |
| 15 01 2026 | Preferential Issue of shares & Inter alia, to consider and approve the following matters: 1. To consider and evaluate a proposal for raising funds through the issuance of one or more instruments, including equity shares, warrants convertible into equity shares, or other securities, by way of preferential issue, private placement or any other permissible mode(s), in accordance with the applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, and other applicable laws, subject to necessary approvals including approval of the shareholders and other statutory/ regulatory authorities, as may be required. |
| 11 02 2026 | Quarterly Results |
News
No News data available
